Ono Entered into a Drug Discovery Collaboration Agreement with PeptiDream to Discover and Develop Macrocyclic Constrained Peptide Therapies
- PeptiDream to receive up-front, research funding & success-based milestones on research, development & commercialization along with royalties based on global net sales. Ono to get an exclusive global right to develop & commercialize drug candidates
- Using PeptiDream’s Peptide Discovery Platform System technology, PeptiDream will be responsible to identify & optimize macrocyclic constrained peptide drug candidates for multiple targets of interest chosen by Ono & with high binding affinity to drug discovery targets
- The new collaboration focuses to advance peptide drug discovery efforts & bring innovative drugs for patients. In Mar 2021, Ono signed a non-exclusive license agreement with PeptiDream on automated PDPS platform technology
Ref: Ono | Image: Ono
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.